CoChat

A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy

Open access

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

Malaria during pregnancy, particularly Plasmodium falciparum malaria, has been linked to increased morbidity and mortality, which must be reduced by both preventive measures and effective case management. The World Health Organization (WHO) recommends artemisinin-based combination therapy (ACT) to treat uncomplicated falciparum malaria during the second and third trimesters of pregnancy, and quinine plus clindamycin during the first trimester. However, the national policies of many African countries currently recommend quinine throughout pregnancy. Therefore, the aim of this article is to provide a summary of the available data on the safety and efficacy of artemether-lumefantrine (AL) in pregnancy. An English-language search identified 16 publications from 1989 to October 2011 with reports of artemether or AL exposure in pregnancy, including randomized clinical trials, observational studies and systematic reviews. Overall, there were 1,103 reports of AL use in pregnant women: 890 second/third trimester exposures; 212 first trimester exposures; and one case where the trimester of exposure was not reported. In the second and third trimesters, AL was not associated with increased adverse pregnancy outcomes as compared with quinine or sulphadoxine-pyrimethamine, showed improved tolerability relative to quinine, and its efficacy was non-inferior to quinine. There is evidence to suggest that the pharmacokinetics of anti-malarial drugs may change in pregnancy, although the impact on efficacy and safety needs to be studied further, especially since the majority of studies report high cure rates and adequate tolerability. As there are fewer reports of AL safety in the first trimester, additional data are required to assess the potential to use AL in the first trimester. Though the available safety and efficacy data support the use of AL in the second and third trimesters, there is still a need for further information. These findings reinforce the WHO recommendation to treat uncomplicated falciparum malaria with quinine plus clindamycin in early pregnancy and ACT in later pregnancy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1475-2875-11-141

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow diagram showing the number of records retrieved, screened and included in this review article. Records were identified by searching publication and clinical trial databases. Duplicates were removed and the remaining records were screened based on their titles, abstracts or clinical trial information. Based on this screen, records judged not to feature any data on the subject of artemether or AL safety, efficacy or pharmacokinetics in human pregnancy were excluded. Of 57 full text articles assessed for eligibility, 39 articles were excluded as they did not include specific reports of artemether or AL exposures during pregnancy and two articles were excluded to avoid duplication of pregnancy exposures. Sixteen relevant articles were therefore identified and included in this review article *1948–2011; **English-language articles. All years; †All years; ICTRP, International Clinical Trials Registry Platform.
Figure 1 Flow diagram showing the number of records retrieved, screened and included in this review article. Records were identified by searching publication and clinical trial databases. Duplicates were removed and the remaining records were screened based on their titles, abstracts or clinical trial information. Based on this screen, records judged not to feature any data on the subject of artemether or AL safety, efficacy or pharmacokinetics in human pregnancy were excluded. Of 57 full text articles assessed for eligibility, 39 articles were excluded as they did not include specific reports of artemether or AL exposures during pregnancy and two articles were excluded to avoid duplication of pregnancy exposures. Sixteen relevant articles were therefore identified and included in this review article *1948–2011; **English-language articles. All years; †All years; ICTRP, International Clinical Trials Registry Platform.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Research works printed but not linked: 2

  1. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Sugiarto P, Tjitra E, Anstey NM, Price RN: Highly effective therapy for malaria in pregnancy improves maternal and neonatal health outcome [abstract]. Am J Trop Med Hyg. 2011, 85 (Suppl 6): Abstract number 455-
  2. Ugandan Malaria Control Programme: Ugandan National Policy on Malaria. 2005, http://www.health.go.ug/mcp/NationalPolicyonMalariaTreatment(07_03_06).pdf ,

Cited by

See all 62

Metadata

Authors
Manyando, C., Kayentao, K., D’Alessandro, U., Okafor, H. U., Juma, E., & Hamed, K.
Affiliations
  • Tropical Diseases Research Centre (ZM)
  • Malaria Research and Training Center (ML)
  • MRC Unit the Gambia (GM)
  • University of Nigeria (NG)
  • Kenya Medical Research Institute (KE)
Corresponding author
Manyando, Christine
Venue
Malaria Journal
Published
2012-05-01
Volume
11
Issue
1
Pages
141-141
ISSN
1475-2875 (ISSN-L)
OpenAlex
W2099127084
Cited by
62
References
51
Citations by year
2026: 1 · 2025: 3 · 2024: 1 · 2023: 3 · 2022: 2 · 2020: 2 · 2019: 1 · 2018: 4 · 2017: 7 · 2016: 11 · 2015: 9 · 2014: 10 · 2013: 7 · 2012: 1
FWCI
1.35
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/2.0 (tdm)
Locations
  • Malaria Journal (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Novartis Pharma
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
Keywords
artemether-lumefantrine, falciparum malaria, malaria in pregnancy, uncomplicated malaria, artemisinin-based combination therapy, drug safety in pregnancy, drug efficacy, sulfadoxine-pyrimethamine, first trimester exposure, pharmacokinetics in pregnancy, adverse pregnancy outcomes
MeSH terms
Artemether, Lumefantrine Drug Combination, Antimalarials, Drug Combinations, Ethanolamines, Female, Fluorenes, Humans, Pregnancy, Pregnancy Complications, Infectious, Pyrimethamine, Quinine, Sulfadoxine, Malaria, Falciparum, Treatment Outcome, Artemisinins, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy. https://app.cochat.ai/papers/10.1186/1475-2875-11-141
The paper
Manyando, C., Kayentao, K., D’Alessandro, U., Okafor, H. U., Juma, E., & Hamed, K. (2012). A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy. Malaria Journal. https://doi.org/10.1186/1475-2875-11-141

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.